- Research & Development
- About us
- Invest in us
- Malaria & medicines
Interactive R&D portfolio
MMV’s portfolio focuses on delivering efficacious medicines that are affordable, accessible and appropriate for use in malaria endemic areas. Specifically, the goal is to develop products that will provide: efficacy against drug-resistant strains of Plasmodium falciparum, potential for intermittent treatments (infants and pregnancy), safety in small children (less than 6 months old), safety in pregnancy, efficacy against Plasmodium vivax (including radical cure), efficacy against severe malaria, and transmission-blocking treatment.
The MMV project portfolio is updated quarterly.
- Download MMV Supported Projects, 2Q 2015 [350Kb]
- Download the global malaria portfolio, 2Q 2015 [470Kb]
- Download the global malaria portfolio, classified by therapeutic type, 2Q 2015 [625Kb]
For more information about the global malaria portfolio, read the article: Malaria medicines: a glass half full? This Review, published in Nature Reviews Drug Discovery, discusses how the antimalarial drug discovery pipeline has changed over the past 10 years, grouped by the various target compound or product profiles, to assess progress and gaps, and to recommend priorities.